Development and Characterization of a Peptide-Bisphosphonate Nanoparticle for the Treatment of Breast Cancer

In women, breast cancer (BC) is the most common cancer, and despite advancements in diagnosis and treatment, 20–30% of early stage BC patients develop metastatic disease. Metastatic BC is deemed an incurable disease, which accounts for 90% of BC related deaths, with only 26% of metastatic patients r...

Full description

Saved in:
Bibliographic Details
Published inMolecular pharmaceutics Vol. 21; no. 10; pp. 4970 - 4982
Main Authors Glass, Kimberley, Fines, Cory, Coulter, Paula, Jena, Lynn, McCarthy, Helen O., Buckley, Niamh
Format Journal Article
LanguageEnglish
Published United States American Chemical Society 07.10.2024
Subjects
breast cancer
nanomedicine
RALA
bisphosphates
risedronate
Online AccessGet full text
ISSN1543-8384
1543-8392
1543-8392
DOI10.1021/acs.molpharmaceut.4c00299

Cover